Epstein Secrets

63> (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health." The drug

reuters.com/article/us-health-coronavirus-gilead/gileads-remdesivir-gets-u-s-fda-approval- for-hospitalized-covid-19-patients-idUSICBN2772XQ> (10/22, Beasley) reports that despite positive results from NIH and the new approval, "the World Health Organization (WHO) last week said its global trial of COVID-

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

though the FDA "will still allow the drug's use in certain cases under its previous emergency authorization" for patients under 12. Reuters (10/22, Beasley) reports that despite positive results from NIH and the new approval, "the World Health Organization (WHO) last week said its global trial of COVID-

e AP (10/22, Marchione) reports that the "antiviral medicine given to hospitalized patients through an IV," being marketed by manufacturer Gilead as Veklury, "cut the time to recovery by five days - from 15 days to 10 on average - in a large study led by the U.S. National Institutes of Health." The drug

ough the FDA "will still allow the drug's use in certain cases under its previous emergency authorization" for patients under 12. Retiterc (10/22, Beasley) reports that despite positive results from NIH and the new approval, "the World Health Organization (WHO) last week said its global trial of COVID-